Orchard Capital Management LLC Takes Position in Intellia Therapeutics, Inc. $NTLA

Orchard Capital Management LLC bought a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the second quarter, Holdings Channel reports. The fund bought 79,503 shares of the company’s stock, valued at approximately $1,345,000. Intellia Therapeutics makes up 1.3% of Orchard Capital Management LLC’s portfolio, making the stock its 26th biggest holding.

A number of other large investors also recently bought and sold shares of the business. Oppenheimer & Co. Inc. boosted its position in shares of Intellia Therapeutics by 0.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock worth $945,000 after purchasing an additional 808 shares in the last quarter. Comerica Bank increased its holdings in Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after buying an additional 901 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Intellia Therapeutics by 36.4% during the first quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock valued at $46,000 after purchasing an additional 948 shares during the last quarter. Wealthfront Advisers LLC lifted its holdings in shares of Intellia Therapeutics by 7.6% during the 1st quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock valued at $185,000 after buying an additional 1,018 shares during the period. Finally, Benjamin Edwards Inc. boosted its stake in shares of Intellia Therapeutics by 1.8% in the 2nd quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock worth $591,000 after buying an additional 1,126 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 4,677 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total transaction of $44,315.98. Following the sale, the chief accounting officer directly owned 66,886 shares in the company, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by corporate insiders.

Intellia Therapeutics Stock Up 3.2%

NASDAQ:NTLA opened at $12.84 on Friday. The business’s 50-day simple moving average is $13.47 and its two-hundred day simple moving average is $13.35. The stock has a market cap of $1.80 billion, a PE ratio of -3.82 and a beta of 1.81. Intellia Therapeutics, Inc. has a 52 week low of $7.95 and a 52 week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, meeting the consensus estimate of ($0.80). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The business had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. During the same quarter in the prior year, the firm earned ($0.98) EPS. The business’s revenue was down 46.4% on a year-over-year basis. Sell-side analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on NTLA shares. Chardan Capital upped their price objective on Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Wall Street Zen downgraded shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. The Goldman Sachs Group lifted their price target on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research note on Tuesday, April 28th. Wolfe Research downgraded shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price objective for the company. in a research report on Wednesday, July 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, eight have assigned a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics presently has an average rating of “Hold” and a consensus target price of $21.15.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.